WO2011056655A3 - Use of cell lines to determine levels of efficacy of pharmaceutical formulations - Google Patents
Use of cell lines to determine levels of efficacy of pharmaceutical formulations Download PDFInfo
- Publication number
- WO2011056655A3 WO2011056655A3 PCT/US2010/054296 US2010054296W WO2011056655A3 WO 2011056655 A3 WO2011056655 A3 WO 2011056655A3 US 2010054296 W US2010054296 W US 2010054296W WO 2011056655 A3 WO2011056655 A3 WO 2011056655A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- efficacy
- cell lines
- pharmaceutical formulations
- determine levels
- assays
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
Abstract
The present invention provides methods and assays for determining the efficacy of pharmaceutical compositions. Through the use of cell lines to measure efficacy of a formulation, one can better measure characteristics such as half life, release rate and release profile of a product that may be informative to the FDA. These methods and assays may, for example, be of use when measuring the effect of anti-inflammatory agents on cytokine production that is being considered for local administration.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/607,199 | 2009-10-28 | ||
US12/607,199 US20110097748A1 (en) | 2009-10-28 | 2009-10-28 | Use of cell lines to determine levels of efficacy of pharmaceutical formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011056655A2 WO2011056655A2 (en) | 2011-05-12 |
WO2011056655A3 true WO2011056655A3 (en) | 2011-07-28 |
Family
ID=43898751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/054296 WO2011056655A2 (en) | 2009-10-28 | 2010-10-27 | Use of cell lines to determine levels of efficacy of pharmaceutical formulations |
Country Status (2)
Country | Link |
---|---|
US (1) | US20110097748A1 (en) |
WO (1) | WO2011056655A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040086246A (en) * | 2001-12-21 | 2004-10-08 | 이스턴 버지니아 메디컬 스쿨 | Method for analyzing effects of medical agents |
US20070243599A1 (en) * | 2005-12-30 | 2007-10-18 | Centocor Research & Development, Inc. | Method for determining the phenotype of cells |
US7575868B2 (en) * | 1996-07-12 | 2009-08-18 | Precision Therapeutics, Inc. | Methods for assessing efficacy of chemotherapeutic agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9224956D0 (en) * | 1992-11-28 | 1993-01-20 | Euro Dpc Ltd | Improvements relating to allergen testing & apparatus |
US5728541A (en) * | 1996-07-12 | 1998-03-17 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
US7815944B2 (en) * | 2001-06-20 | 2010-10-19 | Metaproteomics, Llc | Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity |
WO2005026348A1 (en) * | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Screening method |
US9132085B2 (en) * | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
-
2009
- 2009-10-28 US US12/607,199 patent/US20110097748A1/en not_active Abandoned
-
2010
- 2010-10-27 WO PCT/US2010/054296 patent/WO2011056655A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7575868B2 (en) * | 1996-07-12 | 2009-08-18 | Precision Therapeutics, Inc. | Methods for assessing efficacy of chemotherapeutic agents |
KR20040086246A (en) * | 2001-12-21 | 2004-10-08 | 이스턴 버지니아 메디컬 스쿨 | Method for analyzing effects of medical agents |
US20070243599A1 (en) * | 2005-12-30 | 2007-10-18 | Centocor Research & Development, Inc. | Method for determining the phenotype of cells |
Also Published As
Publication number | Publication date |
---|---|
WO2011056655A2 (en) | 2011-05-12 |
US20110097748A1 (en) | 2011-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011153157A3 (en) | Benzoquinolone inhibitors of vmat2 | |
AU2013293116A8 (en) | Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides | |
IL224288A (en) | Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof | |
EP2251038A4 (en) | Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both | |
WO2012021715A3 (en) | Stable formulations of linaclotide | |
WO2010123919A3 (en) | Piperidine inhibitors of janus kinase 3 | |
GB0906579D0 (en) | Pharmaceuticals, compositions and methods of making and using the same | |
MX354102B (en) | Benzimidazole-proline derivatives. | |
WO2010048358A3 (en) | Ethoxyphenylmethyl inhibitors of sglt2 | |
WO2009091576A3 (en) | Parenteral formulations of dopamine agonists | |
WO2011017502A3 (en) | Linaclotide-containing formulations for oral administration | |
WO2011131943A3 (en) | Pharmaceutical compositions | |
WO2011106248A3 (en) | Trimethoxyphenyl inhibitors of tyrosine kinase | |
WO2010147830A3 (en) | Aminothiazole modulators of beta-3-adrenoreceptor | |
WO2009115084A3 (en) | Pyrrolopyrimidine derivatives, and use thereof | |
WO2011134962A3 (en) | Orally disintegrating tablet containing acarbose | |
UA110979C2 (en) | Liquid pharmaceutical formulation comprising nitisinone | |
MX2009007764A (en) | Extended release formulation of nevirapine. | |
WO2010033167A3 (en) | Anti-thrombin aptamer formulations and methods for use | |
WO2012075015A3 (en) | Oral metronidazole pharmaceutical compositions | |
WO2013006308A3 (en) | Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders | |
WO2011150457A3 (en) | Haematopoietic-prostaglandin d2 synthase inhibitors | |
WO2010077730A3 (en) | Indanone inhibitors of acetylcholinesterase | |
WO2012003495A3 (en) | Automated equipment for hydration, mixing and delivery of alginate to a pellet forming device | |
EP2983684B8 (en) | Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10828892 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10828892 Country of ref document: EP Kind code of ref document: A2 |